From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
N (%)* | Total | No remission N (%)* | Remission N (%)* | OR (95% CI) | |
---|---|---|---|---|---|
Oligo JIA onset | 194 (49.9) | 389 | 96 (43.8) | 98 (57.6) | 0.6 (0.4-0.9) |
Number of active joints† | 1 (0-3) | 389 | 1(0-3) | 0(0-2) | 1.2 (1.1-1.3) |
Tarsal joint arthritis | 33 (8.5) | 389 | 28 (12.8) | 5 (2.9) | 4.8 (1.8-12.8) |
ESR (OR pr 10 mm/hour)† | 14 (8-29) | 315 | 18 (10-39) | 11 (6-20) | 1.3 (1.2-1.5) |
HLA-B27 positive | 74 (20.4) | 363 | 52 (24.8) | 22 (14.4) | 2.0 (1.1-3.4) |
ANA-IF | 113 (29.8) | 379 | 74 (35.1) | 39 (23.2) | 1.8 (1.1-2.8) |
Patient’s global assessment VAS† | 1.0 (0.2-3.0) | 235 | 1.8 (0.5-3.5) | 0.5 (0.0-2.0) | 1.3 (1.1-11.5) |
CHAQ score† | 0.3 (0.0-1.0) | 241 | 0.6 (0-1.2) | 0.0 (0.0-0.6) | 2.3 (1.5-3.5 |